In this study, we investigated the therapeutic efficacy of a replication -conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB / c mice were developed: ( i ) splenic injection, ( ii ) splenic and subcutaneous ( s.c. ) injection, and ( iii ) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor -specific cytotoxic T -lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor -specific T -cell responses.
L iver metastases of colorectal cancer have been reported to occur in nearly half of patients, the prognosis for which is poor. 1 Patients with untreated liver metastases have a median survival of 5-10 months. 2 Even though surgical resection, the only effective intervention for liver metastasis, can be performed, the 5-year survival rate is only 20-40%. 3, 4 There is a need to develop novel strategies for the treatment of liver metastases of colorectal cancer.
A conditionally replicating herpes simplex virus ( HSV ) vector, G207, was created by deletions in both copies of the ICP34.5 gene, the major determinant of neurovirulence, 5 and E. coli lacZ gene insertion for inactivation of the ICP6 gene. 6 The ICP6 gene encodes the large subunit of HSV ribonucleotide reductase, which is a key enzyme required for DNA synthesis and HSV replication in nondividing but not in dividing cells. 7 Interruption of the ICP6 gene restricts replication of HSV-1 to rapidly dividing cells. Due to these mutations, replication of G207 in normal cells is highly attenuated and, therefore, it replicates within tumor cells and causes tumor cell destruction without local or systemic toxicity. G207 has been used as an antineoplastic agent for the treatment of brain tumors as well as other tumors. 8 -14 Recently, we demonstrated that intratumoral inoculation with G207 induces systemic T-cell responses specific to the tumor antigen. 8, 9, 15 In bilateral established tumor models with murine syngeneic tumors, G207 inoculation into the subcutaneous ( s.c. ) tumors as an in situ cancer vaccine caused growth inhibition of both the inoculated and noninoculated distant tumors. 9, 15 The immunocompetent mice treated intratumorally with G207 generated cytotoxic T-lymphocyte (CTL ) responses against the tumor as well as the antigenic peptide for the tumor.
The murine colorectal carcinoma cell line CT26 has been widely used as a syngeneic tumor model to develop immunotherapy. 16 -18 Implantation of CT26 tumor cells leads to uniform tumor formation and no detectable CTL activity against them. 16, 19 A nonmutated nonamer peptide derived from the envelope protein (gp70 ) of an endogenous ecotropic murine leukemia provirus ( MuLV ), env -1, has been identified as the immunodominant MHC class Irestricted antigen for CT26. 18 Adoptive transfer of peptidespecific CTL lines was able to cure established s.c. CT26 tumors, indicating the involvement of tumor-specific CTL in the antitumor effect. Therefore, we developed three liver metastasis models with the CT26 tumor cells and investigated the efficacy of G207 as an in situ cancer vaccine for the treatment of liver metastases from colorectal cancer.
Materials and methods

Cell lines
CT26 is a colon epithelial tumor, which derived by intrarectal injections of N -nitroso -N -methylurethaneinduced BALB /c mice (H-2 d ). 20 CT26 was cultured in Dulbecco's minimum essential medium (DMEM) containing 10% heat -inactivated fetal calf serum ( IFCS ) and penicillin -streptomycin. Meth A, mouse fibrosarcoma cells ( H-2 d ) 21 (kindly provided by Dr. H. Ikeda, Mie University, Japan ), were maintained in RPMI 1640 containing 10% IFCS, 50 M 2 -mercaptoethanol, 2 mM glutamine, 20 mM HEPES ( N 0 -2-hydroxyethylpiperazine -N 0 -2 -ethanesulfonic acid ) buffer, and penicillin -streptomycin.
Virus
The construction of G207 was described previously. 6 It contains deletions at both copies of the ICP34.5 gene as well as an Escherichia coli lacZ insertion inactivating the ICP6 gene. The ICP34.5 deletion decreases neurovirulence of the virus. 5 Disruption of the ICP6 gene eliminates ribonucleotide reductase activity and increases specificity of the virus for dividing cells such as tumor cells. 7 African green monkey kidney ( Vero cells, ATCC, Rockville, MD ) were maintained in DMEM with 10% IFCS and penicillin -streptomycin. Virus was propagated on Vero cells at multiplicity of infection (MOI ) of 0.01 at 348C. Viral titers were determined by standard plaque assay on Vero cells.
Animal studies
All animal procedures were approved by the Keio University School of Medicine Animal Care and Use Committee. Female BALB /c and BALB /c (nu/nu ) mice ( 5-10 weeks old ) purchased from CLEA Japan ( Tokyo, Japan ) were used in this study. For surgical procedures, each mouse was anesthetized with an intraperitoneal injection of a 0.25-0.30 mL solution consisting of 84% bacteriostatic saline, 10% sodium pentobarbital (1 mg / mL ), and 6% ethyl alcohol.
Liver metastasis models and treatments
Three liver metastasis models in mice were developed: ( i) splenic injection, ( ii) splenic and s.c. injection, and (iii ) orthotopic implantation of CT26 colon carcinoma.
( i ) Intratumoral inoculation with G207 in the splenic injection model. A syngeneic mouse model of liver metastasis by splenic tumor cell injection was developed as previously described 22 with minor modification. Briefly, after making an incision at the left abdomen, CT26 tumor cells (5Â10 5 cells ) in 20 l phosphate -buffered saline ( PBS ) were injected into the spleen of BALB / c or BALB /c Figure 1 Intratumoral inoculation with G207 reduces liver metastasis in the splenic injection model with CT26. BALB / c mice were injected with 5Â10 5 CT26 cells into the spleen and G207 ( 1Â10 7 pfu ) or mock was inoculated into the established splenic tumor on day 7 ( n = 8 / group ). Mice treated with G207 showed significantly fewer liver metastases than control mice. Although splenic tumor volumes were also reduced in the G207 -treated animals compared with the control, they are not statistically different ( P = .066; unpaired t test ). *P < .005; unpaired t test. The results represent the mean ± SEM.
Cancer Gene Therapy
Immuno-viral therapy for liver metastasis T Endo et al ( nu/nu ) mouse with a 27-gauge needle. The spleen was returned to the abdominal cavity. Seven days after tumor cells implantation, mice were inoculated into the established splenic tumor with 1Â10 7 plaque -forming units (pfu ) of G207 in 50 l of virus buffer (150 mM NaCl, 20 mM Tris, pH 7.5) and modified Eagle's medium (1:1 ). Mock -infected extract, prepared from mock -infected Vero cells, was used as a control for virus inoculum. BALB /c and BALB /c (nu /nu ) mice were killed 21 days after tumor cell implantation. Tumor nodules on the surface of livers were macroscopically counted and splenic tumor sizes were measured by external caliper. For pathological studies, some animals were perfused with 2% paraformaldehyde in PBS. Livers were isolated, fixed in 10% neutral -buffered formalin, and embedded in paraffin. Sections were stained with hematoxylin and eosin.
( ii ) Intratumoral inoculation with G207 in the splenic and s.c. injections model. We developed a modified model of liver metastasis by splenic tumor injection with s.c. tumor. CT26 cells ( 5Â10 5 ) were injected into the spleen as well as s.c. in the right flank of BALB /c mice ( day 0 ). Five days after tumor implantation, either 1Â10 7 pfu of G207 or mock was injected into the established s.c. tumor, followed by a second injection 3 days later. Spleen and s.c. tumors were removed on days 8 and 14, respectively. On day 28, mice were killed and liver metastases were evaluated.
( iii ) Intratumoral inoculation with G207 in the orthotopic implantation model. Orthotopic transplantation of colon cancer was performed as previously described 23 with minor modification. Briefly, s.c. CT26 tumors growing in BALB /c mice were removed and the tumor tissues cut into pieces in PBS after aseptic removal of necrotic portions. After making a small incision at the left lower abdomen, the colocecal part of the intestine was exteriorized. One piece of CT26 tumor tissue (approximately 2 mm in diameter ) was transplanted on the wall of the cecum in BALB /c mice and the cecum was returned to the abdominal cavity. Seven days after implantation, mice were intraneoplastically inoculated with either 1Â10 7 pfu of G207 virus or mock. Number of liver metastases and cecal tumor sizes were analyzed 21 days after 
Immuno-viral therapy for liver metastasis T Endo et al tumor implantation. For pathological studies, animals were perfused with 2% paraformaldehyde in PBS. Liver sections were stained with hematoxylin and eosin. To generate effector cells for CTL assays, mice were killed 14 days after virus inoculation and their spleens were harvested.
CTL assay
Single-cell suspensions of splenocytes from individual mice treated with G207 or mock were prepared in ACK lysing buffer ( Bio Whittaker, Walkersville, MD ) followed by washing in RPMI 1640 medium containing 10% IFCS. Effector cells were cultured in RPMI 1640 medium with 10% IFCS, 50 M 2-mercaptoethanol, 2 mM glutamine, 20 mM HEPES, and penicillin -streptomycin in 24-well plates at a concentration of 3Â10 6 cells/mL. In addition, 1Â10
6 inactivated CT26 cells were added to the medium. For inactivation, CT26 tumor cells were incubated for 1 hour in culture medium containing 200 g/ mL of mitomycin C and then washed with PBS two times. Effector cells were harvested after 6 days of in vitro culture. Four-hour 51 Cr release assays were performed as previously described. 9 In brief, target cells were incubated with 50 Ci of Na 51 CrO 4 ( 51 Cr ) for 60 minutes. Target cells were then mixed with effector cells for 4 hours at the effector-to -target ratios indicated. The amount of 51 Cr release was determined by gamma counting, and the percent specific lysis was calculated from triplicate samples as follows: [( experimental cpm À spontaneous cpm )/ (maximum cpm À spontaneous cpm ) ]Â100.
Results
Effect of intratumoral inoculation with G207 on liver metastasis in the splenic injection model
We first evaluated the therapeutic efficacy of intratumoral inoculation with G207 against liver metastasis in a splenic injection model with CT26. BALB /c mice were injected with 5Â10 5 CT26 cells into the spleen and G207 (1Â10 7 pfu ) was inoculated into the established splenic tumor on day 7. A number of tumor nodules on the surface of livers in all mice treated with mock, 21 days after splenic injection of CT26. In contrast, five of eight G207 -treated animals showed no apparent tumor mass on the livers (Table 1 ) . Mice treated with G207 showed significantly fewer liver metastases than control mice (Fig 1 ) . Although splenic tumor volumes were also reduced in the G207 -treated animals compared with the control, they were not statistically different ( Fig 1) , P=.066; unpaired t test ). Histological examination of liver sections revealed numerous tumor masses in a mouse treated with mock (Fig 2A ) . In contrast, no obvious tumor mass was observed in the liver sections of the G207 -treated mouse (Fig 2B ) .
Lack of significant effect of intratumoral inoculation with G207 on liver metastasis in athymic mice
To evaluate the possible role of T cells in the reduction of liver metastases by G207, the therapeutic efficacy of intratumoral inoculation with G207 was tested in athymic mice. BALB /c (nu /nu ) mice were injected with 5Â10 5 CT26 cells into the spleen and G207 (1Â10 7 pfu ) was inoculated into the established splenic tumor on day 7. Mice treated with G207 showed no significant inhibition of either liver metastases or growth of splenic tumors compared with the control mice (Fig 3 ) . No complete responses were observed in the G207 -treated animals ( Table 1 ). The lack of therapeutic effect on liver metastasis in athymic mice indicates the involvement of T cells in this antitumor effect.
Effect of intratumoral inoculation with G207 on liver metastasis in the splenic and s.c. injection model
To confirm the involvement of immune responses in the inhibition of liver metastases by intratumoral inoculation Figure 3 Lack of therapeutic efficacy of intratumoral inoculation with G207 on liver metastasis in athymic mice. BALB / c ( nu / nu ) mice were injected with 5Â10 5 CT26 cells into the spleen and then G207 ( 1Â10 7 pfu ) or mock was inoculated into the established splenic tumor on day 7 ( n = 8 / group ). No significant reduction of either liver metastases or splenic tumor volumes was observed in the G207 -treated animals compared with the controls ( P = .21, P = .49; unpaired t test ). The results represent the mean ± SEM. Figure 4 Intratumoral inoculation with G207 reduces liver metastases in the splenic and s.c. injection model with CT26. CT26 cells ( 5Â10 5 ) were injected into the spleen as well as s.c. in BALB / c mice on day 0. Five days after tumor implantation, either 1Â10 7 pfu of G207 or mock was injected into the established s.c. tumor, followed by a second injection 3 days later ( n = 8 / group ). Liver metastases were significantly fewer in mice treated with G207 compared with mock on day 28. *P < .05; unpaired t test. The results represent the mean ± SEM.
Cancer Gene Therapy
Immuno-viral therapy for liver metastasis T Endo et al with G207, we established a modified model of liver metastasis by splenic and s.c. injections with CT26 in BALB / c mice. Five and 8 days after tumor implantation, G207 (1Â10 7 pfu ) were inoculated into the distant established s.c. tumor. In this model, the antitumor effect on liver metastasis does not involve direct viral cytotoxicity. In order to observe mice for a long time, spleen and s.c. tumors were removed on days 8 and 14, respectively. On day 28 after tumor implantation, liver metastases were significantly reduced in mice treated with G207 compared to mock ( Fig 4 ) . Complete responses were observed in four of eight the G207 -treated animals ( Table 1 ). These results suggest that the therapeutic efficacy of intratumoral inoculation with G207 on liver metastasis involves the induced antitumor immune responses.
Effect of intratumoral inoculation with G207 on liver metastasis in the orthotopic implantation model
Considering clinical application of this therapeutic approach, we also evaluated the therapeutic efficacy of intratumoral inoculation with G207 on liver metastasis in an orthotopic implantation model. A piece of CT26 tumor tissue was transplanted onto the wall of the cecum in BALB/ c mice and G207 ( 1Â10 7 pfu ) was inoculated into the established cecal tumor on day 7. All animals treated with mock showed a number of liver metastases 21 days after implantation of CT26 ( Fig 2C ) . In contrast, five of eight the G207 -treated animals showed no obvious tumor mass on the surface of livers ( Table 1 ) . Histological examination of one of the cured mice revealed no apparent tumor mass in the liver sections ( Fig 2D ) . Mice treated with G207 showed significantly fewer liver metastases than control mice ( Fig 5 ) . Cecal tumor volumes were also significantly reduced in the G207 -treated animals compared with the control ( Fig 5 ) .
Intratumoral inoculation with G207 elicits a tumor -specific CTL response in the orthotopic implantation model
To test whether reduction of liver metastases was associated with tumor-specific CTLs after intratumoral inoculation of G207 in the orthotopic implantation model, effector cells were generated in vitro from splenocytes obtained 14 days after G207 inoculation and 51 Cr release assays were performed. Mice treated with G207 generated CTL responses against CT26 cells but not against Meth A cells ( Fig 6) . No specific CTL response was detected in mice treated with mock.
Discussion
The present study evaluates the efficacy of in situ cancer vaccination with the replication -conditional HSV mutant G207 for the treatment of liver metastasis from colon cancer. We have demonstrated that in three different mouse models of liver metastasis, intratumoral inoculation with G207 elicited a significant therapeutic efficacy through the involvement of antitumor T-cell responses.
One of the novel approaches for cancer gene therapy is the use of replication -conditional mutant viruses, such as the HSV mutant G207, 6, 24 and an adenovirus mutant, ONYX -015, that replicates selectively in p53 -deficient tumor cells. 25 -27 Because of limitations regarding vector delivery and low levels of gene transfer using replication -defective viral vectors, novel vectors that can selectively replicate within the tumor and thus increase the efficiency of tumor cell destruction have been developed for cancer therapy. Initial studies with G207 focused on the treatment of malignant brain tumors using local vector delivery to avoid damaging normal brain. 6, 8, 28, 29 The spectrum of target cancers for this oncolytic viral therapy has been expanded to include head and neck cancers, colon cancers, prostate cancers, and bladder cancers after local as well as systemic administration with G207. 9 -11,13,30 These studies were evaluated in athymic mice with human xenografts. Oncolytic viral therapy for liver metastasis of colon cancer has been evaluated in a syngeneic rat model. 11 Introducing G207 by hepatic portal vein infusion showed a significant therapeutic efficacy for liver metastasis. This study also Cr -release assay. Mice treated with G207 generated a specific CTL response against CT26 cells but not against Meth A cells ( n = 3 ). No specific CTL response was detected in mice treated with mock ( n = 3 ). Figure 5 Intratumoral inoculation with G207 reduces liver metastases in the orthotopic implantation model with CT26. A piece of CT26 tumor tissue was transplanted onto the wall of the cecum in BALB / c mice and G207 ( 1Â10 7 pfu ) or mock was inoculated into the established cecal tumor on day 7 ( n = 8 / group ). Mice treated with G207 had significantly fewer liver metastases than control mice. Cecal tumor volumes were also significantly reduced in the G207 -treated animals. *P < .05; **P < .001; unpaired t test. The results represent the mean ± SEM.
Cancer Gene Therapy
Immuno-viral therapy for liver metastasis T Endo et al demonstrated that regional infusion with G207 can be efficient for viral delivery without cytotoxic dissemination to other organs. In addition to the oncolytic activity of G207, it has been demonstrated that systemic antitumor immune responses can be elicited. In a bilateral established s.c. tumor model with CT26 cells in BALB /c mice, intratumoral inoculation with G207 caused a significant growth inhibition in both the inoculated and contralateral noninoculated tumors.
9,15 G207 inoculations into s.c. tumor induced specific CTL responses to HSV as well as the tumor antigen. Although the exact mechanism of induction of antitumor immunity by G207 is still unclear, activation of circulating antigen -presenting cells ( APCs ) by HSV at the tumor site appears to be critical. 31, 32 Viral destruction of tumor cells may release tumor antigens that are then picked up by activated APCs and presented to T cells. Strong T-cell responses against HSV could also help to activate T-cell responses against tumor.
In the splenic injection model, G207 inoculation into the established splenic tumor induced a significant antitumor effect on liver metastasis. The antitumor effect on liver metastasis could be mediated by viral oncolytic effects and induced antitumor immune responses. In athymic mice, however, the antitumor effect on liver metastasis was missing, suggesting that the efficacy of intratumoral inoculation with G207 involves T-cell responses. Furthermore, in the splenic and s.c. injection model, similar antitumor effects on liver metastases were observed by G207 inoculation into the distant established s.c. tumor. It has been demonstrated that HSV inoculation into s.c. tumor induces specific CTL responses to the tumor antigen. 9, 15, 31, 32 In addition, after G207 inoculation into s.c. tumor, expression of -gal, which is the marker gene of G207 was observed in the s.c. tumor; however, all other organs including brain, lung, liver, spleen, and colon were negative for -gal ( data not shown ). These data suggest that the therapeutic efficacy of intratumoral inoculation with G207 on liver metastasis may depend on induced antitumor immunity, and not direct viral cytopathic effect.
Considering clinical application of this therapeutic approach, we developed an orthotopic implantation model with syngeneic colon carcinoma in mice and evaluated the therapeutic efficacy on liver metastasis. Previous studies have indicated that implanting human tumor cells orthotopically in the corresponding organ of nude mice resulted in higher metastatic rates, including human lung cancer, 33 bladder cancer, 34 breast cancer, 35 and colon cancer. 23 Tumor cells inoculated into an orthotopic site where the microenvironment is similar to that of their original organ can develop not only local growth but also metastasis. In our preliminary experiments, mice were sacrificed at different days after CT26 tumor implantation and liver metastasis was evaluated macroscopically. On day 21, we observed liver metastases in all mice examined and, thereafter, mice became severely sick with multiple metastases to other organs including the peritoneum and lung. Therefore, we analyzed liver metastasis on day 21 in this orthotopic implantation model with CT26. Intratumoral inoculation with G207 into the established cecal tumor elicited a significant therapeutic effect on liver metastases, as well as CTL responses specific to the tumor in the spleen. G207 is currently being tested in a clinical trial for the treatment of recurrent glioma. 24 It has been reported that direct intracranial inoculation of G207 at 3Â10 9 pfu causes neither acute toxicity, viral shedding, nor clinically evident delayed reactivation of the virus. Histological examination revealed that no evidence of encephalitis or HSV-1 antigen was detected in brain specimens from any patients. 24 Liver metastases are present at multiple sites in approximately half the cases and often cannot be surgically removed 1 . Current treatment strategies have failed to improve the survival of patients, even when combinations of several different modalities are used. Considering their accessibility by means of endoscopic surgery, in situ cancer vaccination with G207 can be a novel and effective therapeutic approach for liver metastases from colon cancer.
